SCHEMBL2950719

SCHEMBL2950719

N#CCOc1ccc2cc(-c3cnc(Cc4ccccc4)o3)ccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38
CDK1 P06493 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
ROCK1 Q13464 1/20 0.38
DYRK1A Q13627 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941497 0.92 LMNA (0.42) MAPK1NOTUMLMNAFFAR1NPSR1
SCHEMBL2945132 0.83 TSHR (0.52) MAPK1LMNANPSR1SMN1; SMN2MAPT
SCHEMBL2942935 0.83 CYP11B1 (0.49) MAPK1DYRK1ALMNANPSR1SMN1; SMN2
SCHEMBL2942318 0.81 PTPN7 (0.53) LMNAFFAR1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL2946398 0.78 FFAR1 (0.39) MAPK1AURKADAPK3JAK2ROCK2
SCHEMBL2943242 0.78 ESR2 (0.47) MAPK1AURKADAPK3JAK2ROCK2
SCHEMBL2951660 0.78 NOTUM (0.43) MAPK1AURKADAPK3JAK2ROCK2
SCHEMBL2943816 0.76 PTPN7 (0.56) MAPK1LMNAFFAR1NPSR1MAPT
SCHEMBL2950785 0.76 CYP1A2 (0.46) MAPK1DYRK1ALMNANPSR1MAPT
SCHEMBL2950936 0.76 PPARG (0.59) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 MAPK1 2104/4885AURKA 3723/4885DAPK3 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.